Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 411-419

  Liu, Xuan ^a,b   Zhang, Junjian ^a   Sun, Dong ^a   Fan, Yuanteng ^a   Zhou, Hongbin ^b   Fu, Binfang ^b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF ARTS AND SCIENCE   (China)

Author keywords

Brain derived neurotrophic factor; Cognition; Fluoxetine; Improvement; Neuroplasticity; Vascular dementia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COGNITION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; FEMALE; FINGER SPAN TEST; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NAUSEA; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SECONDARY PREVENTION; TEN POINT CLOCK DRAWING; VERBAL FLUENCY TEST; XEROSTOMIA;

BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; FLUOXETINE; IMPROVEMENT; NEUROPLASTICITY; VASCULAR DEMENTIA;

AGED; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; DEMENTIA, VASCULAR; FEMALE; FLUOXETINE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84896040742     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S58830     Document Type: Article

References (57)

1. Rockwood K, Ebly E, Hachinski V, et al. Presence and treatment of vascular risk factors in patients with vascular cognitive impairment. Arch Neurol. 1997;54:33-39.
2. Zhou DH, Wang JY, Li J, et al. Frequency and risk factors of vascular cognitive impairment three months after ischemic stroke in china: the Chongqing Stroke Study. Neuroepidemiology. 2005;24:87-95.
3. François Chollet JT, Jean-François Albucher. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME) a randomised placebo- controlled trial. Lancet Neurol. 2011;10:123-130.
4. Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG. Escitalopram and enhancement of cognitive following stroke. Arch Gen Psychiatry. 2010;67:187-196.
5. Donald R, Royall MD. Sertraline improves executive function in patients with vascular cognitive impairment. J Neuropsychiatry Clin Neurosci. 2009;21:445-454.
6. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.
7. Schinder AF, Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 2000;23:639-645.
8. Pencea V, Bingaman KD, Wiegand SJ, et al. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci. 2001;21:6706-6717.
9. Yamada K, Nabeshima T. Brain-derived neurotrophic factor/ TrkB signaling in memory processes. J Pharmacol Sci. 2003;91: 267-270.
10. Psotta L, Lessmann V, Endres T. Impaired fear extinction learning in adult heterozygous BDNF knock-out mice. Neurobiol Learn Mem. 2013;103:34-38.
11. Calabrese F, Guidotti G, Racagni G, et al. Reduced neuroplasticity in aged rats: a role for the neurotrophin brain-derived neurotrophic factor. Neurobiol Aging. 2013;34:2768-2776.
12. Matrisciano F, Bonaccorso S, Ricciardi A, et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res. 2009;43:247-254.
13. Lee HY, Kim YK. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology. 2008;57:194-199.
14. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70-75.
15. Piccinni A, Marazziti D, Catena M, et al. Plasma and serum brain- derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord. 2008;105: 279-283.
16. Deuschle M, Gilles M, Scharnholz B, et al. Changes of serum concentrations of brain-derived neurotrophic factor (BDNF) during treatment with venlafaxine and mirtazapine: role of medication and response to treatment. Pharmacopsychiatry. 2013;46:54-58.
17. Malberg JE. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104-9110.
18. Nibuya M. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Arlington, VA, USA: American Psychiatric Publishing, Inc.; 2000.
20. Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997;49:1096-1105.
21. Folstein MF, Folstein SE, McHugh PR. Mini-mental state A practi- cal method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
22. Manos PJ, Wu R. The Ten Point Clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. Int J Psychiatry Med. 1994;24:229-244.
23. Wechsler D. Wechsler Memory Scale (WMS-III). San Antonio, TX, USA: Psychological Corporation; 1997.
24. Benton A, Hamsher K, Varney N, Spreen O. Contribution to Neuropsychological Assessment: New York, NY, USA: Oxford University Press; 1983.
25. Karege F, Perret G, Bondolfi G, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143-148.
26. Chang YC, Tzeng SF, Yu L, et al. Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobiol Dis. 2006;24:101-113.
27. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007;27:67-70.
28. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair. 2008;22: 311-314.
29. Schmitt JA, Wingen M, Ramaekers JG, et al. Serotonin and human cognitive performance. Curr Pharm Des. 2006;12:2473-2486.
30. Sambeth A, Riedel WJ, Tillie DE, et al. Memory impairments in humans after acute tryptophan depletion using a novel gelatin-based protein drink. J Psychopharmacol. 2009;23:56-64.
31. Feeney DM, De Smet AM, Rai S. Noradrenergic modulation of hemiplegia: facilitation and maintenance of recovery. Restor Neurol Neurosci. 2004;22:175-190.
32. Maya Vetencourt JF, Sale A, Viegi A, et al. The antidepressant fluox- etine restores plasticity in the adult visual cortex. Science. 2008;320: 385-388.
33. Peng Q, Masuda N, Jiang M, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol. 2008;210:154-163.
34. Geldmacher DS, Waldman AJ, Doty L, et al. Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition. J Clin Psychiatry. 1994;55:161.
35. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.
36. Laske C, Stransky E, Leyhe T, et al. Decreased brain-derived neurotrophic factor (BDNF)- and beta-thromboglobulin (beta-TG)- blood levels in Alzheimer's disease. Thromb Haemost. 2006;96:102-103.
37. Pliego-Rivero FB, Bayatti N, Giannakoulopoulos X, et al. Brain-derived neurotrophic factor in human platelets. Biochem Pharmacol. 1997;54: 207-209.
38. Yamamoto H, Gurney ME. Human platelets contain brain-derived neurotrophic factor. J Neurosci. 1990;10:3469-3478.
39. Radka SF, Holst PA, Fritsche M, et al. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res. 1996;709: 122-301.
40. Fujimura H, Altar CA, Chen R, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost. 2002;87:728-734.
41. Nakahashi T, Fujimura H, Altar CA, et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. 2000;470:113-117.
42. Donovan MJ, Miranda RC, Kraemer R, et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol. 1995;147:309-324.
43. Braun A, Lommatzsch M, Mannsfeldt A, et al. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol. 1999;21: 537-546.
44. Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999;189:865-870.
45. Poduslo JF, Curran GL. Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res. 1996;36:280-286.
46. Pan W. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37:1553-1561.
47. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328:261-264.
48. Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol. 2012;47:816-824.
49. Navaratna D, Guo SZ, Hayakawa K, et al. Decreased cerebrovascular brain-derived neurotrophic factor-mediated neuroprotection in the diabetic brain. Diabetes. 2011;60:1789-1796.
50. Amoureux S, Lorgis L, Sicard P, et al. Vascular BDNF expression and oxidative stress during aging and the development of chronic hypertension. Fundam Clin Pharmacol. 2012;26:227-234.
51. Rantamaki T, Hendolin P, Kankaanpaa A, et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology. 2007;32:2152-2162.
52. Kozisek ME, Middlemas D, Bylund DB. The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment. Neuropharmacology. 2008;54: 251-257.
53. Surget A, Saxe M, Leman S, et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry. 2008;64:293-301.
54. Li Y, Luikart BW, Birnbaum S, et al. TrkB regulates hippocampal neurogenesis and governs sensitivity to antidepressive treatment. Neuron. 2008;59:399-412.
55. Gunstad J, Benitez A, Smith J, et al. Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. J Geriatr Psychiatry Neurol. 2008;21:166-170.
56. Lee JG, Shin BS, You YS, et al. Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Psychiatry Investig. 2009;6:299-305.
57. Yasutake C, Kuroda K, Yanagawa T, et al. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci. 2006;256:402-406.